Skip to main content

Advertisement

SpringerLink
Log in

Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Goals of work

This is a prospective clinical study aimed at assessing the success rate of osteotomy and primary wound closure in patients with bisphosphonate-associated osteonecrosis of the jaw (BONJ).

Materials and methods

Fifty patients who had received bisphosphonates intravenously and subsequently suffered from BONJ were included in the study. All patients underwent osteotomy of the affected jaw bone region and primary wound closure under general anaesthesia. They were followed up bimonthly for a period of 12 months.

Results

Macroscopically altered bone could be completely removed in all cases. In two patients with plasmocytoma, major bleeding occurred postoperatively that required monitoring in an intensive care unit. In two cases, recurrence of BONJ was diagnosed during the first 2 months. In three patients, recurrence appeared between the fourth and the sixth month. In these cases, an additional osteotomy had to be performed. Six patients died during the follow-up period. In the remaining 39 patients, no signs of recurrence could be detected during the follow-up of 12 months. The success rate of the surviving patients was 89% after 1 year.

Conclusion

Due to the high success rate of osteotomy and primary wound closure, it should be checked for every patient suffering from BONJ if osteotomy is a viable treatment option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. AAOMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376

    Article  Google Scholar 

  2. Adornato MC, Morcos I, Rozanski J (2007) The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 138:971–977

    PubMed  Google Scholar 

  3. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G (2007) Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 18:1071–1075

    Article  PubMed  Google Scholar 

  4. Biasotto M, Chiandussi S, Dore F, Rinaldi A, Rizzardi C, Cavalli F, Di Lenarda R (2006) Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol Scand 64:348–354

    Article  CAS  PubMed  Google Scholar 

  5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  6. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869

    Article  CAS  PubMed  Google Scholar 

  7. Carter GD, Goss AN (2003) Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48:268

    Article  CAS  PubMed  Google Scholar 

  8. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736–1740

    Article  CAS  PubMed  Google Scholar 

  9. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:259–260

    Article  PubMed  Google Scholar 

  10. Groetz KA, Al-Nawas B (2006) Persisting alveolar sockets—a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64:1571–1572

    Article  PubMed  Google Scholar 

  11. Grotz KA, Kreusch T (2006) Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation (Wissenschaftliche Stellungnahme der DGZMK, AG Kieferchirurgie und DGMKG). Dtsch Zahnärztl Z 61:510–513

    Google Scholar 

  12. Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573–580

    Article  PubMed  Google Scholar 

  13. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836

    Article  CAS  PubMed  Google Scholar 

  14. Kademani D, Koka S, Lacy MQ, Rajkumar SV (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81:1100–1103

    Article  PubMed  Google Scholar 

  15. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Article  PubMed  Google Scholar 

  16. Klingemann HG, Egbring R, Havemann K (1981) Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma. Scand J Haematol 27:253–262

    CAS  PubMed  Google Scholar 

  17. Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournie B (2002) Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand’s syndrome. Seven new cases with a literature review. Jt Bone Spine 69:62–67

    Article  CAS  Google Scholar 

  18. Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602–2608

    CAS  PubMed  Google Scholar 

  19. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  20. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575

    Article  PubMed  Google Scholar 

  21. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77:109–117

    CAS  PubMed  Google Scholar 

  22. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658–1668

    CAS  PubMed  Google Scholar 

  23. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C (2007) Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:473–477

    Article  PubMed  Google Scholar 

  24. Nkenke E, Schultze-Mosgau S, Radespiel-Troger M, Kloss F, Neukam FW (2001) Morbidity of harvesting of chin grafts: a prospective study. Clin Oral Implants Res 12:495–502

    Article  CAS  PubMed  Google Scholar 

  25. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R (2007) Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 92:1289–1290

    Article  PubMed  Google Scholar 

  26. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanisms of action of bisphosphonates. Bone 24:73S–79S

    Article  CAS  PubMed  Google Scholar 

  27. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157

    Article  CAS  PubMed  Google Scholar 

  28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  29. Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66–S80

    Article  PubMed  Google Scholar 

  30. Sarin J, Derossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277–285

    Article  CAS  PubMed  Google Scholar 

  31. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468

    CAS  PubMed  Google Scholar 

  32. Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, Nomura K, Inaba T, Horiike S, Kanamura N, Taniwaki M (2006) Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 84:343–345

    Article  CAS  PubMed  Google Scholar 

  33. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98:665–672

    Article  CAS  PubMed  Google Scholar 

  34. Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61:1238–1239

    Article  PubMed  Google Scholar 

  35. Van den Wyngaert T, Huizing MT, Vermorken JB (2007) Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 19:315–322

    Article  PubMed  Google Scholar 

  36. Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M (2007) Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 45:628–632

    Article  PubMed  Google Scholar 

  37. Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107

    Article  CAS  PubMed  Google Scholar 

  38. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    CAS  PubMed  Google Scholar 

  39. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, Watzinger F, Schicho K, Ewers R, Millesi G (2008) Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30:1224–1230

    Article  PubMed  Google Scholar 

  40. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118:473–478

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Glückstrasse 11, 91054, Erlangen, Germany

    Philipp Stockmann, Falk Wehrhan, Martin Seiss, Friedrich-Wilhelm Neukam & Emeka Nkenke

  2. Department of Oral and Maxillofacial Surgery, University of Athens Medical School, Vas. Sofias 93 & Dim. Soutsou 1, Athens, 11521, Greece

    Eleftherios Vairaktaris

  3. Department of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, Krankenhausstr. 12, 91054, Erlangen, Germany

    Stephan Schwarz

  4. Department of Medicine, Friedrich-Alexander University Erlangen-Nuremberg, Krankenhausstr. 12, 91054, Erlangen, Germany

    Bernd Spriewald

Authors
  1. Philipp Stockmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleftherios Vairaktaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Falk Wehrhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Seiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephan Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernd Spriewald
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Friedrich-Wilhelm Neukam
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Emeka Nkenke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Stockmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stockmann, P., Vairaktaris, E., Wehrhan, F. et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18, 449–460 (2010). https://doi.org/10.1007/s00520-009-0688-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0688-1

Keywords

Search

Navigation